medRxiv preprint doi: https://doi.org/10.1101/2020.09.09.20191031; this version posted September 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody

2 seroprevalence in a low transmission setting

3

\neg Darah wi, more, wali oni, include the finally included a solution of the second s	arsons. ⁵	² Kate M. F	A. McNamara.	⁴ Havlev	^{2,3} * Teresa Neeman.	¹ * Kai Pohl. ^{2,3}	Sarah M. Hicks.	4
--	----------------------	------------------------	--------------	---------------------	---------------------------------	---	-----------------	---

- 5 Jin-shu He,⁵ Sidra A. Ali,¹ Samina Nazir,¹ Louise C. Rowntree,⁶ Thi H. O. Nguyen,⁶
- 6 Katherine Kedzierska,⁶ Denise L. Doolan,⁷ Carola G. Vinuesa,^{2,8,9} Matthew C. Cook,^{2,9}
- 7 Nicholas Coatsworth,^{10,11} Paul S. Myles,^{12,13} Florian Kurth,³ Leif E. Sander,³ Graham J.
- 8 Mann,¹ Russell L. Gruen,¹⁴ Amee J. George,^{1,5} Elizabeth E. Gardiner,^{1†} Ian A. Cockburn.^{2†#}
- 9 and the SARS-CoV-2 Testing in Elective Surgery Collaborators¹⁵
- 10
- 11 1. ACRF Department of Cancer Biology and Therapeutics, John Curtin School of Medical
- 12 Research, The Australian National University, Canberra, Australia
- 13 2. Department of Immunology and Infectious Disease, John Curtin School of Medical
- 14 Research, The Australian National University, Canberra, Australia
- 15 3. Department of Infectious Diseases and Respiratory Medicine, Charité, Universitatsmedizin
- 16 Berlin, Berlin, Germany
- 17 4. Biological Data Science Institute, John Curtin School of Medical Research, The Australian
- 18 National University, Canberra, Australia
- 19 5. ANU Centre for Therapeutic Discovery, The Australian National University, Canberra,
- 20 Australia
- 21 6. Department of Microbiology and Immunology, Peter Doherty Institute, University of
- 22 Melbourne, Melbourne, Australia.
- 23 7. Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine,
- 24 James Cook University, Cairns, Australia.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 8. China Australia Centre for Personalised Immunology, Shanghai Renji Hospital, Jiaotong
- 26 University, Shanghai, China.
- 27 9. Department of Immunology Canberra Hospital, Canberra, Australia.
- 28 10. ANU Medical School, Australian National University, Canberra, Australia
- 29 11. The Canberra Hospital, Infectious Diseases, Canberra, Australia
- 30 12. Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital, Melbourne,
- 31 Australia.
- 32 13. Department of Anaesthesiology and Perioperative Medicine, Monash University,
- 33 Melbourne, Australia
- 34 14. College of Health and Medicine, Australian National University, Canberra, Australia
- 35 15. See Supplementary Text
- 36
- 37 † and * These authors contributed equally
- 38 #Corresponding Author
- 39
- 40 Running Title: Seroprevalence of SARS-CoV-2 in Australia

- 42 Word count (abstract): 98
- 43 Word count (main text): 1969

otes

45

46	Conflict of Interest Statement: NC is an employee of the Australian Government
47	Department of Health and Ageing contributed to study design, interpretation of results, and
48	approval of the manuscript. All other authors declare no competing interests.
49	
50	Funding: The study was sponsored by the Australian Government Department of Health and
51	Ageing and Medibank Private.
52	
53	
54	Corresponding Author Contact Details: <u>ian.cockburn@anu.edu.au</u> +61 (0)2 6125 4619
55	Department of Immunology and Infectious Disease, John Curtin School of Medical Research,
56	The Australian National University, Canberra, Australia

58 Abstract

59

69

60	Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate
61	assay sensitivity and specificity. Using an ELISA-based approach to that combines data
62	about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens,
63	we show that near-optimal sensitivity and specificity can be achieved. We used this assay to
64	assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in
65	Australia and estimated seroprevalence in Australia to be 0.28% (0 to 0.72%). These data
66	confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and
67	validate the specificity of our assay.
68	

Key words: SARS-CoV-2, COVID19, seroprevalence, ELISA, antibodies

70 Introduction

71

Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely 72 73 to represent only a fraction of actual SARS-CoV-2 infections, as ~40% of cases are mild or asymptomatic, or otherwise undiagnosed [1]. Detection of antibodies that recognize viral 74 antigens specific for SARS-CoV-2 has become an important molecular sentinel of current or 75 76 prior exposure to SARS-CoV-2 [2]. Measurement of antibody levels can provide information 77 regarding the status of infection in an individual, as well as indicate the rate and extent of 78 response to treatment and to recovery. Since a significant number of people either present with mild symptoms of COVID19 infection or are asymptomatic, serological measurements 79 80 will have ongoing utility in gauging exposure and prevalence in the community [3]. Such 81 studies will provide valuable information on the time course and longevity of antibody 82 responses to SARS-CoV-2 [4]. Further, serological testing is likely to be valuable in the assessment of vaccine efficacy. However, analyses of seroprevalence, especially in low 83 84 prevalence settings are hampered by assays with inadequate sensitivity and specificity [5]. 85 Australia has reported low case numbers of COVID-19 per head of population compared to 86 other developed Westernized countries, especially before the July/August 2020 outbreak in 87 88 Melbourne, Victoria (Australian Department of Health). Efforts to control the spread of the 89 virus have likely been helped by relative geographical isolation and an advanced healthcare system. However nucleic acid testing generally only reveals a fraction of the total numbers of 90

infections thus the overall numbers of previous infections is unknown [3, 6]. Nonetheless it is 91 92 likely that the total of previously infected individuals is low as a proportion of the population (<1%) and thus assessment of seroprevalence requires the use of highly sensitive and specific 93 94 methodologies. In order to assess the seroprevalence of SARS-CoV-2 in Australia we

- therefore developed a dual-antigen ELISA assay which gave superior sensitivity and 95
- 96 specificity compared to assays that rely on single antigens.

97 Materials and Methods

98

99 *Samples and ethics statement*

100

101	Collection of blood from individuals pre-2020 was carried out after provision of informed
102	consent, using procedures approved by the Human Research Ethics Committees (HREC) of
103	the Australian National University (2016/317) and ACT Health (1.16.011 and 1.15.015).
104	Samples from SARS-CoV-2 positive individuals were collected after consent under the
105	following protocols: Alfred Hospital HREC (280/14); James Cook University HREC
106	(#H7886); ACT Health HREC (1.16.011): Charité Ethics Committee (EA2/066/20) [7].
107	Approval for the elective surgery study was given by Alfred Hospital Ethics Committee
108	(339/20) and the Australian National University (2020/379). Whole blood was collected by
109	venipuncture into an empty syringe (healthy donors) or a red capped serum vacutainer tube
110	(patients), rested for 1 h then centrifuged (1000g, 10 min, 4°C) and the upper serum phase
111	removed by aspiration to a new tube and immediately frozen. All samples were heated to
112	56°C for 1 h prior to analysis.

113

114 ELISA protocol

115

Our ELISA protocol was based on previously published methodologies with modifications
[8]. Briefly, white 96-well maxisorp microtitre plates (Nunc 436110) were coated overnight
at 4°C with 100 µL of 500 ng/mL Spike RBD (GenScript, Z03483) or Nucleocapsid
(GenScript, Z03480) protein in 1X Dulbecco's phosphate-buffered saline (PBS) pH 7.4
(Sigma D1408). Wells were washed three times with PBS containing 0.2% (v/v) Tween-20
(PBS-T), blocked with 100 µL 3% (w/v) BSA in PBS with 0.1% (v/v) Tween-20 for 1 h at

122	room temperature (RT), then washed once with PBS-T, before addition of 50 μ L serum
123	diluted to 1:100 in 1% (w/v) BSA in PBS with 0.1% (v/v) Tween-20. Plate washing was
124	performed by repeated plunging of plates into a bucket filled with PBS-T and flicking of well
125	contents into a sink. After 1 h incubation at RT, wells were washed five times with PBS-T
126	and incubated with 100 μ L of horseradish peroxidase (HRP)-conjugated anti-human IgG,
127	IgM or IgA antibodies diluted to the optimal concentration in 1% BSA (w/v) in PBS with
128	0.1% Tween-20 for 1 h at RT. Wells were washed five times with PBS-T then 100 μL of
129	Super Signal ELISA Pico enhanced chemiluminescent (ECL) substrate (Pierce, Rockford, IL,
130	USA) was added and light emission (stable after 1 min) was measured using a Victor-Nivo
131	luminescence plate reader. For high throughput screening of samples, steps downstream of
132	sample addition were automated as outlined in the supplementary materials and methods.
133	
134	Statistical analysis
135	
136	ELISA data was expressed as the normalized Log_{10} emission at 700nm. ROC analysis and
137	cutoffs were determined using GraphPad Prism 8 software. Estimates of seroprevalence were
138	calculated using R with 95% confidence intervals were calculated by bootstrapping. Bayesian
139	analysis to determine the probability of positivity for each sample was determined using R
140	based on the distributions of the positive and negative values described as mixed
141	distributions. Full details of statistical analysis and R codes are given the Supplementary
142	Materials and Methods.

143 Results

144

145 Optimization of manual and automated ELISA protocol conditions

146

147	To optimize our assay we used a library of 184 serum samples collected pre-2020 as negative
148	controls, and a panel of 43 sera from individuals infected with SARS-CoV-2 as positive
149	controls. Initial optimization of assay conditions was carried out with defined pools of sera
150	from 5 positive donors and 5 negative donors. Noting that even small gains in specificity can
151	substantially reduce the number of false negatives in large sero-surveys, we optimized the
152	concentration and amount of antigen used for coating, blocking and washing conditions.
153	Overall, we found that the principal factors affecting assay performance were the coating
154	conditions and the necessity of stringent washing (Table S1 and Figure S1).
155	
156	To handle large numbers of samples we optimized our ELISA assay for automation. We
157	investigated the use of an enhanced chemiluminescence (ECL) substrate as these substrates
158	have superior sensitivity compared to traditional colorimetric absorbance substrates such as
159	O-phenylenediamine dihydrochloride (OPD) [9] and do not require a stopping step
160	facilitating automation. Comparing different protocols to distinguish our responses to the N
161	antigen in positive and negative donors we determined that ECL was marginally superior to
162	OPD with a larger separation between positive and negative control values (Figure S2 A and
163	B). Importantly, conducting the analysis on a robotic platform did not compromise assay
164	sensitivity and specificity (Figure S2 C-D).
165	

166 *Combing IgG responses to multiple antigens gives optimal sensitivity and specificity*

168 Having established optimal ELISA conditions, we wanted to determine the optimal antigen, or combination of antigens for seroprevalence surveys. We therefore compared responses to 169 the full S1 domain of the Spike protein (S1), Nucleocapsid protein (N) and the receptor 170 171 binding domain (RBD) of the Spike protein. Overall, the sensitivity and specificity of responses to the N and RBD were comparable, with the N protein being slightly superior 172 (Figure 1 A and B). Surprisingly, the S1 protein gave very poor sensitivity and specificity 173 with many negative samples giving high values (Figure S3). We next investigated the 174 175 possibility of combining data for both antigens. Plotting responses to the RBD and N 176 antigens revealed that even the less responsive positive control samples generally had at least 177 elevated responses to both antigens (Figure 1C). Thus, using the mean of the responses to the RBD and N responses, we found that a cutoff of 1.302 gave 100% sensitivity and 98.91% 178 179 specificity (Figure 1D). Neither IgA nor IgM responses distinguished positive and negative 180 donors as well as IgG, and averaging IgA or IgM responses to both antigens did not 181 substantively improve the assay (Figure S4).

182

183 The seroprevalence of SARS-CoV-2 is low in Australia

184

We next used our dual-antigen IgG ELISA to assess the seroprevalence of SARS-CoV-2 185 186 infection among 2991 individuals, providing blood samples at 10 hospital sites across 4 states 187 in Australia in May and June 2020. These individuals were enrolled in a prospective cohort study to determine the prevalence of asymptomatic SARS-CoV-2 infection in individuals 188 189 undergoing elective surgery in Australia; full demographic information is given in the full 190 manuscript describing this prospective cohort study separately (Coatsworth et al. Submitted). In our initial screen 41/2991 were above our cutoff of 1.302 (Figure 2A), correcting for the 191 192 specificity of our assay we calculated the seroprevalence to be 0.28% (0 to 0.71%). To

193 confirm our positive results, we retested the top 2.7% of samples from each site in parallel 194 with our complete set of positive and negative control samples. In this analysis 15 individuals remained above the 100% specificity cutoff (Figure 2B), however plotting the RBD and N 195 196 values showed that only 5 samples were strongly positive for both antigens, clustering with 197 our positive controls. In contrast the remaining 10 putative positives were close to the cutoff 198 and were in many cases strongly positive for only one or other antigen, thus we reasoned these might be false positives. Of note, 1/5 (20%) of our high-confidence positive samples 199 200 was a contact of a known SARS-CoV-2+ individual, compared to 14/2986 (0.47%) in the 201 remainder of the cohort (p=0.0248 by two-tailed Fisher's exact test; odds ratio=53.1 (4.07-357) giving us confidence that our assay was detecting true positive individuals. 202 203 204 To avoid biases associated with the use of cutoffs we also calculated the probability of each 205 of our 80 retested samples being positive based on the known distributions of the positive and 206 negative results (Figure 2C). This analysis determined that the top 6 samples each had a 207 >50% (58-99%) probability of being positive, while the remaining 9 potentially positive samples had individual probabilities of being positive of 10-47%. By summing the 208 209 probabilities of positivity among these samples we can estimate that ~ 8 (0.27%) individuals in our cohort would be positive which is similar to our original estimate of seroprevalence. 210

211 Discussion

212

Here we report results from the first large scale seroprevalence survey in Australia. We 213 214 estimate a seroprevalence of 0.28%, which - given a population estimate for Australia of 25.50 million individuals - equates to 71,400 infections (95% CI: 0 to 181,050). At start of 215 sample collection (2nd June) 7387 cases/102 deaths had been reported in Australia, rising to 216 11,190 cases/116 deaths by 17th July when sample collection finished suggesting that testing 217 218 was capturing 10-15% of cases and that there was a low case fatality rate, similar to other 219 jurisdictions with high testing rates [10]. Note that due to the small number of positive samples we have not attempted to stratify our analysis based on the demographic 220 221 characteristics of our cohort. A key caveat of our study is that the positive controls used for 222 assay validation are skewed to hospitalized individuals and thus we do not know with 223 certainty the performance characteristics of the assays for asymptomatic cases who are 224 known to have lower antibody levels [4, 11]. Moreover, a recent study has suggested that 225 asymptomatic cases may not always seroconvert, though the assays used there had lower sensitivity than we report for our assay [5, 11]. Overall however, these data suggest that the 226 227 low case number seen in Australia was reflective of low community transmission not inadequate testing. This is supported by the fact that the subsequent outbreak in Melbourne in 228 229 July/August 2020 emerged from breaches of hotel quarantine of overseas travelers rather than 230 undetected community transmission.

231

A variety of assays of have been put forward for the assessment of seroprevalence of 232

233 antibodies to SARS-CoV-2. Lateral flow devices were used in early studies, but these devices

have insufficient sensitivity and specificity for use in low prevalence settings [12]. However, 234

235 more recent studies using ELISA based assays with greater statistical rigor have overcome

~~~	C .1 ·	1 •	1.1.1	C	1 •	1 • 1	
236	some of these issues	and given	reliable estimate	es of seroprev	alence in	higher-	transmission
				bo or beropre,		TTT STTAT	vi wiibiiiibbioit

- areas such as the United States [3, 13, 14]. More recently, commercial
- electrochemiluminescence-based assays have been developed that offer high degrees of
- sensitivity and specificity as well as standardization [6, 15]. However, these assays only
- assess IgG responses to a single antigen and are relatively expensive. By combining results
- from responses to antigens and using convergent statistical approaches we show how an
- assay that can be established in ordinarily equipped laboratories can obtain credible estimates
- 243 of SARS-CoV-2 seroprevalence, even in low transmission settings.
- 244

# 245 Acknowledgements

246

247 The authors acknowledge the contributions of all participants, study sites, local investigators,

surgical and anaesthetic teams, the study coordinators Sophie Wallace and Lucy Morris.

249

## 251 References

- 253 1. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative
- 254 Review. Ann Intern Med 2020; 173:362-7.
- 255 2. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
- 256 COVID-19. Nat Med 2020; 26:845-8.
- 257 3. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10
- 258 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020.
- 4. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of
- asymptomatic SARS-CoV-2 infections. Nat Med **2020**; 26:1200-4.
- 261 5. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological
- assays informs future diagnostics and exposure assessment. Nat Commun **2020**; 11:3436.
- 263 6. Pollan M, Perez-Gomez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain
- 264 (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;
- 265 396:535-44.
- 266 7. Kurth F, Roennefarth M, Thibeault C, et al. Studying the pathophysiology of coronavirus
- disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-
- 268 19). Infection 2020; 48:619-26.
- 269 8. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
- seroconversion in humans. Nat Med **2020**; 26:1033-6.
- 9. Samineni S, Parvataneni S, Kelly C, Gangur V, Karmaus W, Brooks K. Optimization,
- 272 comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich
- ELISA for measurement of human IL-23. J Immunoassay Immunochem 2006; 27:183-93.
- 274 10. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-
- 275 CoV-2 in Iceland. N Engl J Med 2020.

- 276 11. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in
- 277 convalescent individuals with asymptomatic or mild COVID-19. bioRxiv
- **278 2020**:2020.06.29.174888.
- 279 12. Bond K, Nicholson S, Lim SM, et al. Evaluation of serological tests for SARS-CoV-2:
- 280 Implications for serology testing in a low-prevalence setting. J Infect Dis 2020.
- 13. Flannery DD, Gouma S, Dhudasia MB, et al. SARS-CoV-2 seroprevalence among
- parturient women in Philadelphia. Sci Immunol **2020**; 5:eabd5709.
- 283 14. Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A. Prevalence of
- 284 SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in
- 285 New York City. J Gen Intern Med 2020; 35:2485-6.
- 286 15. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott
- 287 Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol
- **288 2020**; 58:e00941-20.
- 289

# Figure 1



290

Figure 1: Combining IgG responses to different antigens improves sensitivity and 291

292 specificity. IgG responses to the N antigen (a) and RBD antigen (b) among positive and

negative control samples and corresponding ROC curve used to determine the 100% 293

sensitivity and specificity cutoffs for ELISAs using that antigen (dashed black lines on 294

295 graph); individual data and mean  $\pm$  SD shown. (c) Relationship between responses to the N

and RBD antigens among positive and negative control samples, dashed lines represent the 296

100% specificity and sensitivity cutoffs derived from the mean of the IgG responses to the N 297

- 298 and RBD antigens. (d) Mean responses to the N and RBD antigens among positive and
- 299 negative control samples and corresponding ROC curve.
- 300





Figure 2 Estimation of seroprevalence of SARS-CoV-2 in Australia (a) Normalized 303 averaged responses to the RBD and N antigens for each of the 2991 individuals in the study 304 separated by study site and state. (b) Anti-N and anti-RBD responses for the top 2.7% 305 306 samples from each site (n=80) compared to the positive and negative controls; the circled 307 unknown sample was a contact of a SARS-CoV-2+ individual. (c) Frequency distribution of the negative, positive and unknown samples (bars) plotted against the calculated probability 308 of positivity in a Bayesian model based on the distributions of the positives and negative 309 310 samples. 311